Suppr超能文献

曲马多/右酮洛芬有何用?

What place is there for tramadol/dexketoprofen?

出版信息

Drug Ther Bull. 2018 Jun;56(6):66-68. doi: 10.1136/dtb.2018.6.0635.

Abstract

No single analgesic provides effective pain relief in all patients and increasing the dose of an analgesic may increase its unwanted effects.1 In addition, pain frequently results from multiple mechanisms that may respond to different pharmacological interventions.2 One suggested approach is to combine analgesics with different modes of action, with the aim of delivering better analgesia using lower doses of each drug.1 Skudexa (A. Menarini Farmaceutica Internazionale SRL), a combination of tramadol hydrochloride (a synthetic opioid analgesic that is a partial agonist at the μ, δ and κ opioid receptors) and dexketoprofen (a NSAID), is licensed for short term treatment of moderate to severe acute pain in adults.1-4 Here, we consider the evidence for this product and how it fits with current guidance on the management of pain.

摘要

没有一种单一的镇痛药能在所有患者中提供有效的疼痛缓解,而且增加镇痛药的剂量可能会增加其不良反应。此外,疼痛常常由多种机制引起,这些机制可能对不同的药理干预有反应。一种建议的方法是将具有不同作用方式的镇痛药联合使用,目的是以较低的每种药物剂量提供更好的镇痛效果。Skudexa(A. Menarini Farmaceutica Internazionale SRL)是盐酸曲马多(一种合成阿片类镇痛药,是μ、δ和κ阿片受体的部分激动剂)和右酮洛芬(一种非甾体抗炎药)的组合,被批准用于成人中度至重度急性疼痛的短期治疗。在此,我们考虑该产品的证据以及它如何符合当前疼痛管理指南。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验